Insurers Reject Most Oral Blood Cancer Prescriptions
A nationwide claims study finds most first-submitted specialty oral blood cancer prescriptions are rejected by U.S. insurers, with many approved drugs never filled.
Updated on Nov. 2, 2026 in Cancer
Live Poll
Do you trust your health insurer to approve and cover prescribed medications fairly?
A study published in the Journal of Clinical Oncology found that insurers rejected 64.9% of Medicare and 84% of commercial prescriptions for specialty oral blood cancer drugs at first submission. Within 90 days, 30.5% of approved Medicare and 17.4% of approved commercial prescriptions were never filled.
Why it matters
Specialty oral anticancer drugs are a key treatment option for blood cancers, and prescriptions that go unfilled can delay or interrupt care. The findings highlight how prior authorization, formulary restrictions and out-of-pocket costs shape patient access nationwide.
The study tracked 12,134 Medicare and commercially insured patients who received new prescriptions in 2022, with first-fill out-of-pocket costs averaging $933 for Medicare and $775 for commercial patients. Medicare fill rates ranged from 76.7% to 84.9% when costs were at or below $175, and the effect of Medicare's 2026 $2,100 out-of-pocket cap on fill rates has not yet been measured.
The players
Perelman School of Medicine at the University of Pennsylvania
A leading medical school whose researchers led the study, and which is widely recognized for its cancer and clinical research programs.
Blood Cancer United
A national patient advocacy organization, formerly known as the Leukemia & Lymphoma Society, that funded the study and works on blood cancer patient access issues.
MD Anderson Cancer Center
A major cancer treatment and research institution in Houston, Texas, that contributed a research team to the study.
The details
Researchers at the Perelman School of Medicine at the University of Pennsylvania led the study with teams from MD Anderson Cancer Center, Yale and Columbia, funded by Blood Cancer United. Prior authorization and formulary restrictions accounted for most initial rejections, and commercially insured patients had more than three times the adjusted odds of rejection compared to Medicare beneficiaries.
Timeline
2022: Patients received the new specialty oral blood cancer prescriptions tracked by the study.
2026: Medicare's $2,100 annual out-of-pocket cap took effect.
2026: A CMS prior authorization rule took effect, excluding prescription drugs.
Big Picture
Medicare Part D treats anticancer drugs as a protected class, requiring plans to cover all or substantially all of them, while commercial insurers operate without an equivalent federal mandate. The study's gap between Medicare and commercial rejection rates shows how that federal protection narrows but does not eliminate access barriers.
Patients prescribed specialty oral blood cancer drugs may face rejections and high first-fill costs that can delay treatment. Out-of-pocket costs at or below $175 were associated with higher Medicare fill rates, so cost is a practical factor to raise with prescribers and plans.
The takeaway
Patients who receive a rejection should ask their prescriber about prior authorization steps and appeals before assuming treatment is unavailable. Checking expected out-of-pocket costs before the first fill can help avoid prescriptions going unfilled.
Further reading
Explore more on Cancer coverage and treatment access.
Source note: This article includes information reported by Insurance Business.
Live Poll
Do you trust your health insurer to approve and cover prescribed medications fairly?
